We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-10.1%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$792M
AUM Growth
-$198M
Cap. Flow
-$55.2M
Cap. Flow %
-6.96%
Top 10 Hldgs %
71.73%
Holding
49
New
10
Increased
7
Reduced
13
Closed
11

Top Buys

1
PRTA icon
Prothena Corp
PRTA
+$77.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.4M
3
SLDB icon
Solid Biosciences
SLDB
+$19M
4
XCUR icon
Exicure
XCUR
+$14.1M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$10.1M

Top Sells

1
CRSP icon
CRISPR Therapeutics
CRSP
+$75.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$51.9M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.7M
4
KURA icon
Kura Oncology
KURA
+$22M
5
GOSS icon
Gossamer Bio
GOSS
+$15.4M

Sector Composition

1 Healthcare 78.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.44M 0.44%
44,221
-553,490
-93% -$51.9M
MRUS
27
DELISTED
Merus
MRUS
$2.95M 0.37%
+165,600
New +$2.72M
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.88B
$2.63M 0.33%
61,554
-436,345
-88% -$23.7M
SURF
29
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.2M 0.28%
1,548,888
-763,800
-33% -$1.67M
RUBY
30
DELISTED
Rubius Therapeutics, Inc
RUBY
$2.04M 0.26%
260,152
-203,000
-44% -$2.37M
VCEL icon
31
Vericel Corp
VCEL
$2.38B
$1.98M 0.25%
131,001
– –
IGMS
32
DELISTED
IGM Biosciences
IGMS
$1.77M 0.22%
+100,000
New +$2.02M
LRMR icon
33
Larimar Therapeutics
LRMR
$384M
$1.44M 0.18%
+162,042
New +$1.78M
QNCX icon
34
Quince Therapeutics
QNCX
$18.5M
$1.25M 0.16%
+250
New +$1.54M
ASMB icon
35
Assembly Biosciences
ASMB
$531M
$950K 0.12%
+8,050
New +$1.22M
AUTL
36
Autolus Therapeutics
AUTL
$383M
$859K 0.11%
+69,155
New +$914K
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$755K 0.1%
104,909
-6,202
-6% -$50.5K
UBX
38
DELISTED
Unity Biotechnology
UBX
$314K 0.04%
5,140
-99,310
-95% -$7.03M
CRSP icon
39
CRISPR Therapeutics
CRSP
$4.71B
– –
-1,610,250
Closed -$75.8M
GOSS icon
40
Gossamer Bio
GOSS
$83.2M
– –
-772,096
Closed -$15.4M
KZR
41
DELISTED
Kezar Life Sciences
KZR
– –
-58,329
Closed -$4.5M
MRSN
42
DELISTED
Mersana Therapeutics
MRSN
– –
-55,689
Closed -$5.64M
RYTM icon
43
Rhythm Pharmaceuticals
RYTM
$7.31B
– –
-223,167
Closed -$4.91M
SYRS
44
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-24,848
Closed -$2.3M
NGM
45
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-316,900
Closed -$4.64M
GMDA
46
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-52,120
Closed -$265K
KDNY
47
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-352,284
Closed -$2.71M
TCRR
48
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-16,114
Closed -$231K
ARQL
49
DELISTED
Arqule Inc
ARQL
– –
-1,300,000
Closed -$14.3M
1
2

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q3 2019 Portfolio in Review

As of Q3 2019, EcoR1 Capital held 49 positions worth $792M, down 20% from $990M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital withdrew a net $55.2M in Q3 2019, closing 11 positions and reducing 13 holdings. Its most notable exit was CRISPR Therapeutics, an estimated $75.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Sarepta Therapeutics worth $14.3M.

  • EcoR1 Capital's largest Q3 2019 buy was Sarepta Therapeutics: 189,745 shares worth $14.3M.
  • EcoR1 Capital added most to Prothena Corp in Q3 2019, an estimated $77.3M increase.
  • EcoR1 Capital's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $51.9M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q3 2019, selling an estimated $75.8M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $792M portfolio in Q3 2019.
  • EcoR1 Capital opened 10 new positions and closed 11 in Q3 2019.
  • EcoR1 Capital's portfolio value fell 20% quarter-over-quarter to $792M.

Based on EcoR1 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.